Penn Medicine’s Neuroendocrine Tumor Program provides comprehensive diagnosis and treatment for neuroendocrine tumors (NETs), including gastroenteropancreatic neuroendocrine tumors, pheochromocytomas, paragangliomas and genetic NET syndromes. Our physicians have extensive experience treating these rare tumors, offering patients cutting-edge treatments from experts that are leaders in their field, all in one place.

NETs affect over 100,000 people in the U.S. alone. These tumors develop in various locations throughout the body from cells with both hormonal (endocrine) and neural (nervous) features. NETs manifest differently in each patient and can affect various primary organs such as the kidneys, intestines, lungs, stomach, pancreas, adrenal glands and thyroid.

A Multidisciplinary Approach to Treatment

Penn physicians are dedicated to delivering comprehensive, high-quality patient care for the treatment of NETs. Penn has one of the only NET programs in the nation with a translational program incorporating both bench research and outstanding clinical care. The Neuroendocrine Tumors Translational Center of Excellence (TCE) is a unique collaborative effort to redefine the diagnostic and therapeutic approaches to NETs, to provide more effective targeted therapies for an underserved group of patients, and to advance research in the development and treatment of NETs.

Using a multidisciplinary approach, our experienced physicians work together to create individualized treatment plans, tailored to the unique needs of each patient. All patients are offered genetic testing and the opportunity to enroll in studies focusing on tumor biology and various clinical trials. Each month, our tumor board, a multispecialty group, comes together to discuss patient cases and treatment plans and approaches.

In This Section

Neuroendocrine Cancer Program

Meet the Penn Medicine clinicians who specialize in neuroendocrine tumors of the bowel and pancreas, pheochromocytomas and paragangliomas (PHEO/PARA).

Share This Page: